Biotech heads to Europe  By Clay Lucas March 31, 2005  Epitan, a
Melbourne biotech company developing a tanning drug through a
slow-release injected implant, will try to raise $37 million by
listing in Britain.  It needs the money to finalise testing of
the tanning drug, called Melanotan, which stimulates production
of melanin in the body.  "Melanin gives you your dark pigment,"
said EpiTan managing director Iain Kirkwood. It helped prevent
sunburn and helped people tan, he said.  EpiTan's Melanotan drug
doubled the body's ability to produce melanin, Mr Kirkwood said.
"As result of that increase, we've proven we can reduce sunburn
injury by up to 50 per cent."  EpiTan would float in Europe
because it believed the market for the drug would be largest in
Europe and North America, where long winters meant people were
susceptible to sun damage when they did get into the sun, or
tanning salons.  "People are heading to tanning salons to get
tans, but the World Health Organisation is now saying that
people with fai